是否应进行挽救性未成熟卵母细胞体外成熟:前景与挑战
该综述回顾性梳理了未成熟卵母细胞体外成熟(IVM)与挽救性IVM(r-IVM)的定义与临床定位,指出经典IVM在未刺激或轻微刺激周期采集卵丘完整卵母细胞时属非实验性,可用于多囊卵巢或PCOS患者;而r-IVM在标准刺激周期取卵后去除卵丘细胞培养,属实验性操作,因成熟率与发育潜能欠佳而临床效力有限,提出需界定合适临床指征。
要点
- 经典IVM为非实验性,可用于多囊卵巢或PCOS患者。
- r-IVM属实验性操作,拟用于降低低成熟率患者的影响。
- r-IVM临床效力有限,需界定合适临床指征。
核心结论
- r-IVM因未成熟卵母细胞成熟与发育潜能欠佳而临床效力有限,由此提出成本/收益问题,即需界定合适的临床指征。
研究设计与样本
- 本文为综述,围绕未成熟卵母细胞体外成熟(IVM)与挽救性IVM(r-IVM)的研究与临床应用进行论述。
主要发现
- 经典IVM在轻微或无卵巢刺激后采集卵丘完整卵母细胞时属非实验性,被提出作为对多囊卵巢或PCOS患者更友好的治疗。
- r-IVM在标准卵巢刺激周期采集未成熟卵母细胞后去除卵丘细胞培养,属实验性操作,缺乏卵丘细胞的代谢与调控支持。
- 生发泡期或减数分裂I期停滞的未成熟卵母细胞需不同体外成熟管理,并表现出不同的发育与染色体能力。
- r-IVM对成熟卵母细胞绝对数高的治疗周期可能无关,而低成熟率、低获卵数和/或低卵母细胞质量的特定 Poor 预后病例可能从单枚体外成熟卵母细胞所得胚胎中获益。
临床怎么用
- 经典IVM为非实验性,被提出作为对多囊卵巢或PCOS患者更友好的治疗。
- r-IVM为实验性操作,作者提出需界定合适的临床指征,并指出其对成熟卵母细胞绝对数高的周期可能无关。
局限性
- r-IVM临床效力有限,归因于未成熟卵母细胞成熟与发育潜能欠佳。
- r-IVM需在去除卵丘细胞后培养,缺乏关键的体细胞代谢与调控支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In vitro maturation (IVM) of immature oocytes has been explored for research and clinical purposes since the dawn of assisted reproductive technologies. Oocyte maturation is a highly specific process, on the basis of complex mutual relationships between the germ and somatic cell compartments. The complexity of this relationship has made the quest for achieving oocyte maturation in vitro arduous. In its classical form, in which intact cumulus-enclosed oocytes are collected after very mild or no ovarian stimulation, oocyte IVM is nonexperimental and has been proposed as a more friendly treatment for patients with polycystic ovary or polycystic ovary syndrome. By contrast, rescue IVM (r-IVM), which is the maturation in vitro of immature oocytes collected in standard ovarian stimulation cycles, is an experimental procedure, proposed to mitigate the impact of low oocyte maturation rates in certain patients. Achieving effective r-IVM has turned out to be an even more daunting task because oocytes are cultured only after cumulus cell removal and, therefore, without the crucial somatic metabolic and regulative support. Immature oocyte arrested at the germinal vesicle or metaphase I stage require different management for their maturation in vitro and exhibit different developmental and chromosomal competence. Therefore, their possible use for treatment suggests a dedicated approach. Overall, r-IVM has limited clinical efficacy due to suboptimal maturation and developmental competence of immature oocytes. This raises a cost/benefit question: that is, the definition of appropriate clinical indications. Rescue IVM is probably irrelevant to treatment cycles in which the absolute number of mature oocytes is high. Conversely, specific poor prognosis cases, involving low maturation rates, low oocyte yield, and/or low oocyte quality, could benefit from the contribution of even a single embryo generated from an in vitro matured oocyte. Future progress in this field will depend on our ability to mimic in vitro the support provided by cumulus cells to oocyte nuclear and cytoplasmic maturation.
引用
- Coticchio G, Cimadomo D, De Vos M, et al. To rescue or not to rescue immature oocytes: prospects and challenges. Fertil Steril. 2025. PMID: 40058555. doi:10.1016/j.fertnstert.2025.02.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。